Adrenal insufficiency development during chemotherapy plus anti-programmed death receptor-1 monoclonal antibody (tislelizumab) therapy in patients with advanced gastric cancer: two case reports

Immune checkpoint inhibitor (ICI)-associated adrenal insufficiency is rare but may become a serious adverse event in patients treated with ICIs. The present case report documents two cases of adrenal insufficiency developed during chemotherapy plus tislelizumab (百泽安, Baize’an; BeiGene Ltd.) therapy...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autor principal: Jin Ho Baek
Format: Artigo
Idioma:Inglês
Publicat: Yeungnam University College of Medicine, Yeungnam University Institute Medical Science 2022-01-01
Col·lecció:Journal of Yeungnam Medical Science
Matèries:
adverse events
immune checkpoint inhibitors
stomach neoplasms
tislelizumab
Accés en línia:http://www.e-jyms.org/upload/pdf/yujm-2021-00934.pdf
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars